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ABSTRACT
Known as the guardian of the genome, transformation-related protein 53 (TRP53)
is a well -known tumor suppressor. Here, we describe a novel TRP53 deficient mouse
model on a tumor prone background—SJL/J mice. The absence of TRP53 (TRP53
nullizygosity) leads to a shift in the tumor spectrum from a non-Hodgkin’s-like
disease to thymic lymphomas and testicular teratomas at a very rapid tumor onset
averaging ~12 weeks of age. In haplotype studies, comparing tumor prone versus
tumor resistant Trp53 null mouse strains, we found that other tumor suppressor,
DNA repair and/or immune system genes modulate tumor incidence in TRP53 null
strains, suggesting that even a strong tumor suppressor such as TRP53 is modulated
by genetic background. Due to their rapid development of tumors, the SJL/J TRP53
null mice generated here can be used as an efficient chemotherapy or immunotherapy
screening mouse model.

INTRODUCTION

tumor development and progression. For example, p53
deficiency synergizes with: Rb deficiency in a conditional
mouse model to produce metastatic prostate cancer
[19]; NUP98 translocation in a NUP98-HOXD13–
driven mouse model to accelerate complications of
myelodysplastic syndrome [20]; and mutations in Apc to
promote mammary neoplasia [21]. Hence, the disrupting
of TRP53 has become a tool to accelerate the growth
of tumors that develop from mutations in other tumor
suppressor genes allowing more rapid and efficient study
of these tumors.
Swiss Jim Lambert (SJL/J) mice, developed from
three different sources of Swiss Webster mice, have
become widely used owing to their high incidence of
reticulum cell sarcomas. They develop lymphomas within
their first year [22-31] that resemble Hodgkin’s disease
[23-25] as well as B-cell non-Hodgkin’s lymphomas
[26-31]. In the presence of IL-21, the tumors arising
from SJL/J mice resemble human angioimmunoblastic
T-cell lymphoma [22]. In addition to cancer models,
these mice have been used as models for experimental
autoimmune encephalomyelitis (EAE) [32], aggression
[33], spontaneous myopathy in limb girdle muscular
dystrophy [34], and cardiovascular disease, due to their

The product of the transformation-related protein
(Trp53) is one of the most researched tumor suppressors
in biomedical research, with currently more than 97,000
research/review articles published to date. Known as the
guardian of the genome, the function of TRP53 protein
(TP53, or, in humans, p53) has been well studied,
and its functions include transcriptional regulation,
DNA repair, cell cycle check-point control, apoptosis,
autophagy and senescence (for review, see [1-9]). The
lack of a functional p53 gene product in humans leads
to Li-Fraumeni syndrome predisposing the patient to a
spectrum of early-onset cancers (for review, see [10-12]).
Importantly, it has been shown that since p53 in humans
is located at a distal end of chromosome 17 (17p13.1),
the loss of this piece of chromosome, and thereby p53,
generally accelerates cancers [3, 13].
Since TRP53 has many crucial functions in
biological systems, a number of mouse models have been
made in order to elucidate TRP53 function more fully
[14-18]. Of principal note here, Trp53 mutations have
been shown to synergize with loss-of-function mutations
in other tumor suppressor genes generally accelerating
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resistance to developing atherosclerotic aortic lesions
even on high fat diet [35]. The SJL/J strain is highly
susceptible to mouse adenovirus 1, making it also a
model for infectious disease studies [36]. Therefore, the
SJL/J strain of mice is a highly valued disease model
to test therapeutics for a diversity of conditions and
diseases.
We previously used these mice to test to what
extent the chemotherapeutic 2-deoxy-D-glucose (2DG)
can alleviate the tumor burden of SJL/J mice exhibiting
terminal stages of cancer [37]. 2DG is a structural
analog to glucose and blocks glycolysis leading to
intracellular ATP depletion, sensitizing tumor cells to
radiation therapy and chemotherapy [38]. However,
2DG at high doses show hypoglycemic and adverse
cardiac effects, and at tolerable doses fail to show a
significant antitumor effect in many in vivo experiments
in both mice and humans [39]. Our 2DG studies in
SJL/J mice were primarily conducted to test to what
extent this toxic chemotherapeutic could have reduced
adverse effects when combined with other compounds.
At doses that did not elicit adverse effects, 2DG alone
given to mice with a SJL/J background was able to
significantly shrink tumors [37]. However, the tumors
develop resistance to 2DG after four weeks, after
which the tumor growth re-emerges [37]. Although the
penetrance of spontaneous tumorigenesis in SJL/J is
>95%, the time it takes to develop such tumors is ~one
year, with a range between nine months to 1.2 years [24].
This protracted pathogenesis means that it is difficult
to generate sufficient cohorts of mice to be tested in a
timely fashion. Therefore, to address this challenge,
we hypothesized that removing Trp53 would accelerate
tumor development, and thereby enable the ability to test
the efficacy of novel combinations of chemotherapies or
immunotherapies within a more operationally convenient
timespan.
Here, we generate a TRP53 null SJL/J mice using
CRISPR Cas9 with two guide RNAs aimed at deleting
exon 4 of the Trp53 gene. Upon analysis, TRP53 was
expressed in +/+ mice, reduced in heterozygous mice,
and absent in -/- mice. Homozygous null mice showed
a significantly shorter time of onset of tumorigenesis,
and a reduced survival, with tumors being detected as
early as 11 weeks of age, faster than all the other models
commonly available. However, we also found that the
ablation of TRP53 in SJL/J mice shifted the tumor
spectrum to thymic lymphomas, testicular teratomas and
rhabdomyosarcomas rather than the typical Hodgkin’s/
non-Hodgkin’s lymphomas that SJL/J wild type mice
develop. This unexpected shift in tumor spectrum to
thymic lymphomas is observed with TRP53 mutations in
other strains such as C57BL6/J, 129S1, BALB/c, FVB/
NJ, and C3H/J, suggesting that deregulation of TRP53
leads to specific types of cancers depending upon the
genetic background [14-18]. We further interrogated
www.Genes&Cancer.com

the haplotypes of these strains, comparing tumor-prone
TRP53 null strains versus the non-tumor-prone strains,
and found that a majority of the alleles that modulate
the tumor incidence rate have either cancer, immune
system or DNA-repair related functions. The immune
system and DNA repair systems are known to be critical
in regulating tumorgenesis. This result suggests that not
even a strong tumor suppressor gene such as Trp53 is
canalized, and the genetic background will modify the
resulting neoplasticity.

RESULTS
Generation of Trp53-/- SJL/J mice
Based on the ENSEMBL database (Release 98),
exon 3 of TRP53 is the first exon that is sufficiently
large enough to generate guides that can target the gene.
Furthermore, functional domains of TRP53 are further
downstream of this exon, thus targeting this exon to
introduce a frame shift mutation is anticipated to lead to
a null mutation. According to the ENSEMBL database,
Trp53 transcripts contain 5’UTR sequences that include
ATG sequences that could be putative translational
start sites. Thus, herein exon 3 is designated as exon 4,
assuming that upstream starts sites yield an additional
exon.
To generate p53 knockout alleles in the SJL/J
mouse strain, superovulated female mice were mated
and zygotes were collected for microinjection. Of the 28
resulting offspring, 15 (54%) had modifications at one
or both target sites; six had deletions of the intervening
sequence between each guide and thus considered
“dropouts.” Founder dropout candidates were crossed
with wild type SJL/J mice and N1 heterozygotes
were genotyped to characterize the mutant alleles.
One allele was ultimately selected to establish a new
mutant mouse strain (Figure 1A, 1B), designated SJL/JTrp53<em2Mvw>/Mvw JAX stock 33940 (i.e. a 176bp
deletion; ∆176). Genotyping and characterization of
mutant alleles was accomplished using PCR (FWD:
5’- TCCAGACTTCCTCCAGAAGATA, REV:5’CCTCTGTGCTTGGCTTCA) and Sanger sequencing.
The wild type PCR product is 624bp and the ∆176
mutant allele results in a 448bp amplicon (Figure 1C).
The mutant allele was maintained in heterozygous
mice. Heterozygous mice were mated to obtain the null,
heterozygous or wild type alleles. Breeding outcomes
showed that the allele frequency was below expected
Mendelian ratios for the homozygotes at 1:3:1=wild
type:heterozygous:null alleles (data from 10 litters, with
litter sizes of ~ 5 mice). However, all mice (i.e., null,
heterozygous, wild type) survive through weaning at a
frequency similar to that of the parental SJL/J strain.
84
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Detection of TRP53 protein

antibody raised against serine 20 of human TRP53,
which cross reacts with mouse TRP53. Western analysis
showed two bands of proteins ~50kD (Figure 1E) as
observed previously [5]. Our western blot observation
and analysis of the ∆176 allele showed no detectable
protein, suggesting that the protein might be degraded
since the antibody raised against serine 20 should
have been able to detect the truncated protein. The
heterozygotes for this allele produce less WT TRP53
than that observed in the wild type littermates (β-tubulin
was used as a loading control (Figure 1E)). In order
to confirm the observed absence of the protein in the
∆176 mutant, we performed an ELISA using antibodies

From the nucleotide sequences, it is predicted
that the ∆176 allele should yield a stop codon after 69
residues (predicted 7.8kDa), leaving the transactivation
domain intact but deleting all domains downstream
(Figure 1D). Intact TRP53 is predicted to be 42.5kD,
however, the protein appears around 53kDa [5]. The
livers, the largest and least affected organ, from a
homozygous null, heterozygous and wild type littermate
from a heterozygous ∆176/+ mating pair were isolated
and lysates probed via western blot with a monoclonal

Figure 1: Generation of SJL/J ∆176.Trp53 mice. A. Design of the guides (sgRNA) targeting exon 4 that resulted in a 176 base
pair deletion (∆176) (WT: wild type). B. Sequencing chromatograms that show the wild type (WT) littermate, the heterozygote mutant
(HET∆176) and the homozygous null mutant (HOM ∆176). C. PCR genotyping assay that shows the wild type (+/+), heterozygous (+/-)
and null (-/-) mice. D. The predicted amino acid sequence resulting in the deletion and generation of a stop codon. Blue and black letters
show the amino acid sequence from alternating exons; red letters show predicted amino acid overlap splice site and green letters show
the new amino acid sequence as a result of the deletion and subsequent frameshift and stop codon (*). E. Western blot of TRP53 and
β-TUBULIN (loading control) showing the absence of the protein in the liver in the -/- mouse, and reduced amount of protein in the +/mice (n = 3 experiments). Arrowheads indicate the position of the TRP53 and tubulin protein. F. Quantification of the amount of TRP53
protein by ELISA in the +/+ (gray bar), +/- (hatched bar) and -/- (white bar) mice (n = 4, 2 duplicate experiments and at 2 concentrations).
Significant differences were determined by the student t-test.
www.Genes&Cancer.com
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Tumor spectrum of the TRP53 null mice

directed towards the N-terminus to confirm the absence
of the protein in mutant mice and to quantify the amount
of protein in wild-type and heterozygous mice (Figure
1F). The ELISA confirmed the western blot results,
revealing that the amount of TRP53 in the livers (10uL
of lysate) was 1929 pg/mL in +/+, 422 pg/mL in the +/and 13 pg/mL in the -/-. Considering the standard error
of detection in the -/- mice was 88 pg/mL, the amount in
the null can be assumed to be zero.

No tumors were detected or observed in the wild
type littermates of the mice at 35 weeks of age. TRP53
null (-/-) SJL/J mice developed thymic lymphomas
(40%), testicular teratomas (40%) or were found dead
without any visible tumors (20%) (Figure 3A). The
heterozygous (+/-) mice developed sarcomas (15%) or
were found dead without tumors, and therefore, noncancer related cause of death (7%) (Figure 3A); none
developed thymic lymphomas or testicular teratomas.
There was no gender bias in the development of thymic
lymphomas, and only half of male SJL/J ∆176.Trp53/- mice developed testicular teratomas. A shift to thymic
lymphomas is consistent with the effects of Trp53
nullizygosity in other strains [14, 16-18],
Upon closer examination of the major types of
tumors derived from +/- and -/- mice, the following
was observed (Figure 3B-3E): The thymic lymphomas
exhibited canonical neoplastic round cells (Figure 3B)
with a high mitotic rate (red arrowheads) of >20 mitotic
figures per high powered field (hpf). Necrosis was
minimal, but there were numerous apoptotic cells (white
circles) throughout the mass. The mice also showed
variable splenomegaly due to infiltration by small
clusters of neoplastic lymphocytes. These features are
typical of Trp53-/- tumors observed in previous models
[14, 16].
The testicular tumor masses which were isolated
from -/- mice were classical teratomas, comprised
of neoplastic tissues from all three germ layers.
Accordingly, the tumors were composed of a mixture
of cell types (Figure 3C): ectoderm (neuropil, red
asterisks), mesoderm (bone, arrow; cartilage, arrowhead;
adipose tissue and muscle), and endoderm (squamous to
columnar ciliated epithelium with goblet cells consistent
with respiratory epithelium, black asterisks). The
neoplastic cells in all of the teratomas had a high mitotic
rate (>20 mitotic figures/hpf), and also showed areas of
necrosis and/or hemorrhage.
The third type of tumor observed in +/- mice but
not in -/- SJL/J mice were rhabdomyosarcomas (Figures
3D). These tumors were composed of neoplastic cells that
were primarily spindle cells, with a smaller proportion
of round cells, as well as some multinucleated cells
(arrows) and strap cells (asterisks). The neoplastic cells
have a high mitotic rate (>10 mitotic figures/hpf) and
mild necrosis was seen in the tumor. The spleens were
large due to plasmacytosis (asterisks), and the red pulp
have a marked increase in megakaryocytes (arrowheads)
(Figure 3E).
In summary, TRP deficiency in a SJL/J background
shifts the cancer spectrum from primarily Hodgkin’s
and non-Hodgkin’s lymphoma to thymic lymphomas,
testicular teratoma and rhabdomyosarcomas.

Survival of Trp53-/- and Trp53+/- mice
Mice carrying the ∆176 allele were further
characterized for tumor spectrum and survival. The
absence of TRP53 significantly (P = 0.02) shortens the
lifespan of the mice from ~one year to a median of 12
weeks (Figure 2). At 35 weeks, all of the homozygous
null mice (N = 5) and four of 14 heterozygous mice had
died, but none of the wild type mice (N = 6) had died.
Three of the 10 heterozygous mice that lived showed
signs of tumorigenesis. The reduction in survival has
been observed before in at least five other strains of mice
with TRP53 mutations, suggesting that regardless of the
genetic background, the loss of TRP53 reduces survival
[14-16, 18].
The SJL/J ∆176.Trp53-/- mice have shown a faster
development of neoplasticity than the tumor prone model
BALB/c, or tumor resistant models, such as C57BL/6
(Table I) which suggests that the genetic background
can modulate the phenotype even of a strong tumor
suppressor such as TRP53.

Figure 2: Survival of SJL/J ∆176.Trp53 mice. Graph

showing a survival curve of -/- (black line), +/- (gray line) and
+/+ littermate (dotted line) mice within the first 35 weeks. See
text for statistical details.
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Incidence and time-of-onset of thymic lymphomas

time-of-onset of thymic lymphomas exceeded 17 weeks in
C57BL6/J or 129S mice, but was only 12 weeks in SJL/J
mice (Table 1). Thus, tumor prone strains have a lower
propensity to develop thymic lymphomas, but develop
them much faster than the more refractive strains. This
suggests that the genetic background may play a role
in modulating the effect of Trp53 nullizygosity. It also
suggests Trp53 knockout in SJL/J mice offer a more
operationally convenient timespan for the study of thymic

As compared to refractive strains such as C57BL6/J
or 129S, which show >65% incidence rate for thymic
lymphomas, fewer SJL/J mice developed thymic
lymphomas (40%), matching more closely to the tumor
prone strain BALB/c (54%) (Table I). However, thymic
lymphomas in the refractive strains took longer to develop
than in the cancer-prone strains. For example, the average

Figure 3: Tumor spectrum of SJL/J ∆176.Trp53 mouse. A. Pie charts showing the tumor spectrum distribution of the +/- and -/mice after 35 weeks. B. Hematoxylin and Eosin (H&E) staining of a thymic lymphoma showing cells with high mitotic rate (red arrows)
and apoptotic cells (circled in white). C. H&E staining of the testicular teratoma showing neoplastic tissues from ectoderm (neuropil, red
asterisks), mesoderm (bone, arrow; cartilage, arrowhead), and endoderm (black asterisks). D. H&E staining of a rhabdomyosarcoma showing
neoplastic cells that are primarily spindle cells, with a smaller proportion of round cells, as well as some multinucleated cells (arrows)
and strap cells (asterisks). E. Splenomegaly was associated with ∆176.Trp53 -/- or +/- mice. Closer examination shows plasmacytosis
(asterisks), and an increase in megakaryocytes (arrowheads) as seen by H&E staining.
www.Genes&Cancer.com
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lymphomas.

and BALB/cJ strains both carry distinct haplotypes.
Included in the tumor resistant phenotype group are also
FVB/NJ and C3H/J, which according to JAX repository
data, develop a similar tumorigenic phenotype as the
C57BL6/J mice (JAX Stock # 002899 and #002547,
unpublished data). Using the known haplotype patterns
that are shared or distinct among strains, we identified
distinct regions that could be associated with putative
tumor spectrum modifiers. Overall, only 0.207% of
the mouse genome (~5.45Mb) exhibited this expected
haplotype profile across these six strains (Figure 4A). We
grouped these haplotypes together based on the genes in
which they harbored into six distinct categories, including
haplotypes that harbored at least one known (i) cancer
gene, (ii) DNA repair gene, (iii) immune system gene, (iv)
non-neoplastic gene, (v) genes with unknown function
and (vi) gene deserts (Figure 4B). After removing gene

Genomic analysis of strain haplotype sharing
nominates putative candidate modifiers of
Trp53-/- mice
The commonly used laboratory mouse strains are
descended from a small founder pool of individuals and
thus only capture a limited amount of genetic diversity.
Across more than 97% of the mouse genome, the genetic
variation present in classical laboratory strains can be
reconciled into fewer than 10 distinct haplotypes. Thus,
we reasoned that putative modifiers of the strain-specific
Trp53-/- tumor spectrum may reside in genomic regions
where the refractive C57BL/6J and 129S1/SvImJ strains
carry the same haplotype, but where the susceptible SJL/J

Figure 4: Patterns of strain haplotype sharing localize candidate regions harboring Trp53-/- modifiers. A. The standard
house mouse karyotype is displayed. Gray dots denote the positions of genomic intervals where the pattern of haplotype sharing among
strains mirror trends in their Trp53-/- tumor spectrum. B. Pie chart showing the function/pathology associated with at least one gene found
in the haplotypes as observed in A. C. Pie chart showing the function/pathology after removing the haplotype that had either no known
genes or genes with unknown function.
www.Genes&Cancer.com
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Table I: Time of onset of neoplasias in Trp53-/- mice
Strain

Mean time of onset neoplasias in weeks incidence rate of thymic lymphomas

Reference

C57BL/6

20.0

0.77

Donehower, et al [16]

C57BL/6J

17.2

0.79

Jacks, et al [14]

129S/J

18.0

0.65

Olive, et al; Donehower, et al [18, 17]

BALB/c

15.4

0.54

Kupperwasser, et al [15]

SJL/J

12.0

0.40

This Study

combinations of chemotherapeutics. As predicted,
Trp53 nullizygosity has accelerated the pace of tumor
development leading to a decrease in survival. The
speed with which these tumors appear is remarkably
fast - 12 weeks on average, as compared to other models
(Table 1). Therefore, this model is useful to study rapid
tumorigenesis in mouse models.
We also showed that a decrease (null) of TRP53
changed the tumor spectrum from a non-Hogdkin’s like
disease to thymic lymphoma in SJL/J mice, similar to
that observed in other strains such as seen in Table I.
When polymorphisms are used to classify similar mice,
BALB/cJ, C57BL/6J and 129S/J are quite diverse from
SJL strains [44, 45]. Yet, thymic lymphomas appear in
all of these strains. The data presented here in Table I
exemplify canalization, which is defined as a measure of
the ability of a population to produce a similar phenotype
regardless of variability of its environment or genotype.
The lack of fully functional TRP53 is a powerful driver
of canalization, that regardless of the genotype leads to a
single major phenotype (i.e., thymic lymphomas).
However, there is a caveat to this conclusion. In the
context of Trp53 nullizygosity, the tumor prone strains
SJL/J and BALB/c show the lowest incidence of thymic
lymphomas but they develop much faster as compared to
C57BL6/J and 129S/J, which show the highest frequency
of thymic lymphomas, but they develop much slower
(Table I). These results lead us to speculate that the link
between Trp53 nullizygosity and tumorigenesis may not
be as simple as the removal of a checkpoint in the cell
cycle, ablation of apoptosis or any one simple step in a
pathway, but a more complex interplay between different
genomes and the propensity to develop cancer.
Based on the notion that the genome can change the
phenotype of an assumed strong canalized gene such as
Trp53, we surveyed the literature and JAX repository data,
and analyzed the genomic differences based on haplotypes
between tumor prone strains and tumor resistant strains.
Here we have identified a number of likely/putative/
probable genomic regions harboring Trp53 modifiers that
make strains such as BALB/cJ and SJL/J tumor prone.
Genetic and functional tests will be required to evaluate
whether and how these putative candidates may modulate
the landscape of tumor formation in the absence of

deserts and unknown function genes, we reanalyzed
these data (Figure 4C). The pie charts generated show
that the majority of the genes in these potential modifier
regions are known to be directly associated with cancer,
or function in DNA repair or the immune system, which
are known to influence and modify tumorigenesis
(Supplementary Figure I). Several compelling candidate
genes reside in these regions, including genes Egfr,
Rad51b, and Foxp1, which all have been shown to modify
p53 tumorigenesis, as discussed below. Therefore, we
have identified the likely/putative/probable genomic
regions harboring Trp53 modifiers that make strains such
as BALB/cJ and SJL/J tumor prone.

DISCUSSION
While the absence of functional TRP53 (also
known as p53 in humans, TP53 in mouse) in humans
causes Li Fraumeni syndrome, the loss of the distal end of
chromosome 17p13.1 has been linked to a wide spectrum
of early-onset cancers and acceleration of tumor growth
[13]. In mice, the loss of TRP53 activity is used to generate
unique mouse models for studies in transcriptional
regulation, cell cycle regulation, apoptosis, and genome
instability [1-3, 5-9, 13-21]. In addition, TRP53 has been
mutated to rescue embryonic lethality. For example, to
study non-homologous end joining in mouse models,
the removal of the Trp53 gene rescues the embryonic
lethal DNA repair protein Ligase IV [43]. Of relevance
to this study, TRP53 nullizygosty was successfully used
to accelerate tumorigenesis in a tumor prone mouse. This
is a unique model that can be used for rapid cancer and
therapeutic studies. In addition, by adding this model to
the library of current TRP53 mutated models, the genetic
haplotypes that modify such as a strong tumor suppressor
can be evaluated.
Based on this evidence, we used CRISPR-Cas9
to delete part of exon 4 (or exon 3 depending on the
functional ATG site, see Figure 1A) on the TRP53 gene,
with the goal that this would generate a TRP53 knockout, since most of the domains for TRP53 function lie
downstream or are a part of this exon. Such a genetic
modification of this gene would lead to an acceleration
of tumorigenesis and facilitate the testing of novel

www.Genes&Cancer.com

89

Genes & Cancer

This study did not analyze the tumor spectrum
of heterozygous mice. In addition, we reported data up
to 35 weeks when a quarter of the heterozygous mice
showed tumors or were found dead. Heterozygous mice
express less than half the amount of TRP53 in their
tissues as compared to wild type tissues. It is understood
that Trp53+/- cells have the propensity to develop loss
of heterozygosity (LOH) depending on the type of cell.
These two aforementioned phenomena, the lowered
amount of TRP53 and LOH, potentially drive the tumor
onset and spectrum in the heterozygous mice [5, 6, 53].
Dissecting the two mechanisms (dose of TRP53 and LOH)
that would contribute to a heterozygous cell’s propensity
to become neoplastic in this tumor prone mouse model is
a subject of future study.
Here, we present a mouse model of Trp53
inactivation in the tumor prone background SJL/J. This
genetic modification of Trp53 leads to rapid tumorigenesis
as compared to current models. Further, apart from the
common thymic lymphomas and rhabdomyosarcomas,
they also exhibit testicular teratomas. These models can
now join the pantheon of Trp53 mutations that can be
used to further dissect the role of TRP53 in the context of
tumor-prone models versus tumor-resistant models, and
reveal genetic and epigenetic cancer etiologies.

Trp53-/-. The function of specific genes such as Egfr,
Rad51b, and Foxp1 have been shown to be modulated
by Trp53 [46-48]. A specific example is that mutations
in p53 amplify EGFR family signaling to promote
mammary tumorigenesis [46]. RAD51B is a homologous
recombination DNA repair protein that interacts with
TRP53 [49, 50], and its activity influences cell cycle
checkpoint control, independent of its role in homologous
recombination in breast cancer [51]. It is also known that
RAD51B, being a homologous recombination protein,
shares its function to maintain genome stability with
TRP53 [52, 53]. FOXP1 is a transcription factor essential
for the development of major organs and known to be a
tumor suppressor in prostrate and breast cancers [54, 55].
In fact, Foxp1 directly represses p53-dependent regulatory
proteins in neoplastic B-cells, suggesting a strong role in
immune modulation [56]. As we currently understand
normal anti-cancer responses, a functional immune system
is a key component that suppresses cancer [57-59]: Foxp1
controls mature B-cell survival and development, and
is a regulator for CD4+ T cells [60, 61]. Thus, it is also
likely that Foxp1 is an essential component that controls
the lymphoid immune system, and thereby a modulator
of tumorigenesis. In all of these cases, there are direct
or indirect mechanisms that could be employed by these
genes to modulate Trp53-dependent tumorigenesis.
Interestingly, known gene products of Trp53
modifiers, such as MDM2, MDM4 and CDKN2A
(p14(ARF)), did not appear in our analysis [2]. It is
possible that the aforementioned genes are modifiers of
Trp53 mutations resulting in different tumor spectrums,
rather than a complete loss or gain of TRP53 that changes
the tumor incidence, which was the analysis done herein.
Genetically Engineered Mouse Models (GEMMS)
are key to testing novel chemotherapy and immunotherapy
compounds [62]. However, tumors may take more than
several months to develop. To shorten tumor latency time,
Trp53 is often deleted [63, 64]. Also, the arising tumors
from a TRP53 null mouse can be directly tested for drug
efficacy studies (for summary see: [62]). This mouse can
be used as a model to test T-cell malignancies, testicular
teratomas and rhabdomyosarcomas, with the advantage
that it is faster than any other available model.
The concept of whether genetic background
influenced the tumor incidence or spectrum of Trp53-/mice was tested decades ago: Donehower et al (1995)
studied Trp53-/- and +/- mice and their wild-type
littermates from either 129Sv or mixed C57BL/6 × 129/Sv.
The 129/Sv mice showed accelerated tumorigenesis (Table
I) compared with p53-deficient counterparts of C57BL/6 ×
129/Sv genetic background, the 129/Sv mice resemble the
C57BL/6 strainwith respect to tumor onset (Table I). This
suggests that the genetic background indeedmodulates
the TRP53 effect on tumor incidence. We have compared
multiple studies (Table I), and show that different genetic
backgrounds can remarkably influence tumor onset.
www.Genes&Cancer.com

MATERIALS AND METHODS
Mice
SJL/J mice used in this study were obtained from,
and bred and housed at The Jackson Laboratory (Bar
Harbor, Maine). Mice were provided food and water ad
libitum and were housed on a 12-hour light, 12-hour dark
cycle. All procedures were approved by The Jackson
Laboratory Institutional Animal Care and Use Committee
(IACUC).

CRISPR mediated knock out of Trp53
Approximately 2-5 picoliters of Cas9 mRNA
(at 100 ng/ul, Trilink), Cas9 protein (at 30 ng/ul,
PNABio), and two sgRNAs (at 50 ng/ul each) were
delivered by microinjection into the pronucleus of
SJL/J zygotes as previously described [40]. Truncated
guides (TRU-sgRNAs) [41] were designed with the
assistance of online software, Breaking Cas [42],
in order to minimize off-target cutting. The guides
were designed to target exon 4 of the Trp53 gene
(target sites: 5’-GAGCTCCTGACACTCGGA and 5’GCCAAGTCTGTTATGTGCA) and were made using
a HiScribe kit (New England Biolabs). Microinjected
zygotes were transferred to pseudopregnant females,
brought to term and screened at two to three weeks of
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age by PCR flanking exon 4. These founder mice were
backcrossed with SJL/J, and resulting mice heterozygous
for the mutation were then inbred to homozygosity.

After washing with TBST for 15min and then with 5 min
washes, the blots were developed with SuperSignal West
Pico PLUS Chemiluminescent Substrate (Fisher Scientific
# PI-34087) and imaged with a G-box (Syngene).

Survival criteria

ELISA for TRP53 quantification

Mice were monitored daily from the time of birth
and diagnosed with a tumor as soon as a visible abnormal
growth appeared. The tumors were allowed to grow until
the mice showed signs of illness and required euthanasia
which then was recorded as the date of death. The need for
euthanasia was independently verified by our Clinical and
Laboratory Animal Medicine personnel. In addition, mice
that were found dead were necropsied and diagnosed for
the cause of death. All mice were terminated at 35 weeks
of age.

Samples used for western blotting (see above)
were quantified using the Abcam Mouse p53 ELISA Kit
(Abcam # ab224878).

Statistics and protein prediction:
For survival curves, P-values were calculated by
log-rank (Mantel-Cox) test using Prism7 v7.0d software.
Protein sizes were predicted from the Protein Calculator
(v3.4) (http://protcalc.sourceforge.net/)

Western blotting

Genome queries

Snap frozen tissues were pulverized with a
Spectrum Bessman Tissue Homogenizer (Fisher Scientific
# 08-418-3) on dry ice. A portion of each tissue was
transferred into a pre-weighed 1.5mL tube and the weight
of each tissue sample was determined. The tissue samples
were subsequently suspended in 100uL of chilled RIPA
(Millipore-Sigma # R0278) with complete mini protease
inhibitors (Roche #11836153001) and PhosSTOP
phosphatase inhibitor (Roche #4906845001) per 40ug of
tissue and homogenized on ice for 10 s with individual
sterile pestles (Fisher Scientific #12-141-364). After 5 min
on ice, homogenization was repeated. After incubating on
ice for a further 30 min with a brief vortex every 5 min, the
samples were spun at 10,000 × g for 10 min at 4°C. The
supernatants were decanted and their protein concentration
determined by the Bradford Assay (Bio-Rad # 500-0205)
using BSA (Bio-Rad # 5000206) for the standard curve.
Gel samples were prepared and denatured at 95°C for 5
min. 50 ug total protein per tissue was separated on 10%
Bis-Tris Protein Gels (Fisher Scientific #NP0302BOX)
with MOPS SDS Running Buffer (Fisher Scientific
#NP0001) in duplicate. The gels were transferred to
nitrocellulose (Fisher Scientific #IB3010-32) using an
iBlot Gel Transfer Device (Fisher Scientific). The blots
were blocked in 3% BSA in 25mM Tris·Cl, 2.7mM KCl,
137mM NaCl and 0.03% TWEEN-20 (TBST) at room
temperature for 1 h. One blot was then placed in p53
(1C12) monoclonal antibody (Cell Signaling Technology
#2524) diluted 1:2000 in 3% BSA-TBST and the second
blot was placed in 3% BSA-TBST with a β-tubulin
antibody (Millipore-Sigma #T4026) diluted 1:10,000.
Both blots were agitated on a shaker at 4oC overnight.
The blots were washed with TBST for 15min and then
with 5 min washes then placed in 3% BSA-TBST with
goat anti-Mouse IgG (H + L)-HRP conjugate (Bio-Rad #
170-6516) diluted 1:20,000 for 1 h at room temperature.
www.Genes&Cancer.com

Genome-wide haplotype strain distribution patterns
were downloaded from the Mouse Phylogeny Viewer
(http://msub.csbio.unc.edu/). A custom Perl script was
used to identify genomic regions harboring a single shared
haplotype between C57BL/6J, FVB/NJ, C3H/HeJ and
129S1/SvImJ, a second distinct haplotype in SJL/J, and a
third haplotype in BALB/cJ. These genomic regions were
then intersected with genes in the mm10 RefSeq database.
We performed a manual inspection of the resulting gene
list to nominate putative modifiers of Trp53 that could
underlie observed strain differences in the tumor spectrum.
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